Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

56.67 -0.91 (-1.58%)
Streaming Delayed Price Updated: 10:23 AM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 Next >
CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Merus N.V. Announces Pricing of Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
What's Going On With Merus Stock Monday?
Merus announced a research collaboration and license agreement with Biohaven. 
Via Benzinga
e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio?
11 mid-cap stocks soared last week, including LZ Technology, Centrus Energy, e.l.f Beauty, Merus, Oklo, NuScale Power, Informatica, BRP, Box, Joby Aviation, and C3.ai. 
Via Benzinga
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
D-Wave Quantum And Advance Auto Parts Are Among Top 7 Mid-Cap Gainers Last Week (May 19-May 23): Are The Others In Your Portfolio?
Top mid-cap stocks gained up to 53.47% in the last week, including QBTS, RGC, AAP, MRUS, OKLO, SBSW, and BGM. Are they in your portfolio? 
Via Benzinga
Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On?
Merus N.V. (NASDAQ: MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab... 
Via Benzinga
Let's take a look at the stocks that are in motion in today's session.
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled
BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday. 
Via Stocktwits
Frontline, Merus, Intuit And Other Big Stocks Moving Higher On Friday
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge. 
Via Investor's Business Daily
Discover the top movers in Friday's pre-market session.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
From Merus N.V.
Via GlobeNewswire
Merus to Present at BofA Securities 2025 Health Care Conference
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Merus Shares Are Up Today: What's Going On?
Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for... 
Via Benzinga
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
This marks the second BTD for petosemtamab in HNSCC 
From Merus N.V.
Via GlobeNewswire
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
From Merus N.V.
Via GlobeNewswire
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Via Benzinga
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
From Merus N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.